🔎 Trials Near Me

Inicio › Linfoma de Burkitt › Idaho

Ensayos clínicos de Linfoma de Burkitt en Idaho

6 estudios sobre Linfoma de Burkitt buscan participantes en Idaho.

Ciudades en Idaho

Texto oficial del estudio (inglés)

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • Saint Alphonsus Cancer Care Center-Nampa, Nampa
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT03739814

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Saint Luke's Cancer Institute - Boise, Boise
ReclutandoFase 2
Edades de 1 a 30 · Todos los sexos · Actualizado el 12 nov 2026 · NCT04546399

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • Saint Alphonsus Cancer Care Center-Boise, Boise
  • Saint Luke's Cancer Institute - Boise, Boise
  • Saint Alphonsus Cancer Care Center-Caldwell, Caldwell
  • y 8 más
ReclutandoFase 3
Edades de 18 a 39 · Todos los sexos · Actualizado el 3 nov 2026 · NCT03150693

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Saint Luke's Cancer Institute - Boise, Boise
ReclutandoFase 2
365 Days · Todos los sexos · Actualizado el 27 oct 2026 · NCT06317662

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Saint Luke's Cancer Institute - Boise, Boise
ReclutandoFase 2
366 Days – 46 Years · Todos los sexos · Actualizado el 27 oct 2026 · NCT06124157

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Saint Luke's Cancer Institute - Boise, Boise
ReclutandoFase 3
365 Days – 25 Years · Todos los sexos · Actualizado el 25 ago 2026 · NCT03959085

De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.